Compare CTBI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | SVRA |
|---|---|---|
| Founded | 1903 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1995 | 2009 |
| Metric | CTBI | SVRA |
|---|---|---|
| Price | $76.52 | $5.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $63.00 | $7.33 |
| AVG Volume (30 Days) | 88.4K | ★ 1.5M |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.02 | N/A |
| Revenue Next Year | $4.30 | $430.87 |
| P/E Ratio | $24.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.25 | $3.08 |
| 52 Week High | $79.92 | $7.01 |
| Indicator | CTBI | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 49.54 |
| Support Level | $72.88 | $5.26 |
| Resistance Level | $78.03 | $6.09 |
| Average True Range (ATR) | 1.19 | 0.26 |
| MACD | -0.51 | 0.00 |
| Stochastic Oscillator | 31.61 | 46.47 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).